Advances in the Development of Site-Specific Antibody-Drug Conjugation

Publisher： Bentham Science Publishers

E-ISSN： 1875-5992|15|7|828-836

ISSN： 1871-5206

Source： Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol.15, Iss.7, 2015-01, pp. : 828-836

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, Iss. 1, 2014-01 ,pp. : 35-65

Bentham Science Publishers

Access to resources Recommend Favorite

Antibody–drug conjugates (ADCs)—new targeted therapies

By Papakonstantinou Georgios  

memo - Magazine of European Medical Oncology, Vol. 6, Iss. 4, 2013-12 ,pp. : 223-224

Springer Publishing Company

Access to resources Recommend Favorite

Orexin 2 receptor as a potential target for immunotoxin and antibody-drug conjugate cancer therapy

By                

Oncology Letters, Vol. 3, Iss. 3, 2012-01 ,pp. : 525-529

Spandidos Publications

Access to resources Recommend Favorite

Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB

By Pollack Vincent   Alvarez Enrique   Tse Kam   Torgov Michael   Xie Sam   Shenoy Suresh   MacDougall John   Arrol Sharon   Zhong Haihong   Gerwien Robert   Hahne William   Senter Peter   Jeffers Michael   Lichenstein Henri   LaRochelle William  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 423-435

Springer Publishing Company

Access to resources Recommend Favorite

Antibody–drug conjugates for the treatment of B-cell non-Hodgkin’s lymphoma and leukemia

By Chu Yu-Waye   Polson Andrew  

Future Oncology, Vol. 9, Iss. 3, 2013-03 ,pp. : 355-368

Future Medicine

Access to resources Recommend Favorite